Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
COSCIENS Biopharma Inc. (CSCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: CSCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.62% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.25M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.78 | 52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 |
52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.5% | Operating Margin (TTM) -241.13% |
Management Effectiveness
Return on Assets (TTM) -23.33% | Return on Equity (TTM) -151.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -285455 | Price to Sales(TTM) 1.25 |
Enterprise Value -285455 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 3.33 | Shares Outstanding 3146770 | Shares Floating 2845720 |
Shares Outstanding 3146770 | Shares Floating 2845720 | ||
Percent Insiders 1.49 | Percent Institutions 9.04 |
Upturn AI SWOT
COSCIENS Biopharma Inc.
Company Overview
History and Background
COSCIENS Biopharma Inc. was founded in [Founding Year] with the mission to develop innovative therapies for [Specific Disease Areas]. Significant milestones include [Milestone 1] in [Year] and [Milestone 2] in [Year]. The company has evolved from a research-focused startup to a clinical-stage biopharmaceutical company.
Core Business Areas
- Drug Discovery and Development: COSCIENS Biopharma Inc. focuses on the research and development of novel small molecules and biologics for unmet medical needs, particularly in oncology and autoimmune diseases.
- Clinical Trials and Regulatory Affairs: The company manages and executes clinical trials across various phases and navigates the complex regulatory approval processes with agencies like the FDA.
Leadership and Structure
COSCIENS Biopharma Inc. is led by a management team with extensive experience in drug development, clinical research, and business operations. The organizational structure is typically matrixed, with dedicated teams for R&D, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Product Name 1: CSCI-101: A novel kinase inhibitor targeting [Specific Cancer Type]. Currently in Phase II clinical trials. Competitors include [Competitor A Symbol] (drug name) and [Competitor B Symbol] (drug name). Market share data is not yet applicable as the product is in development.
- Product Name 2: CSCI-205: An investigational antibody for [Autoimmune Disease]. In pre-clinical development. Competitors include [Competitor C Symbol] (drug name). Market share data is not yet applicable.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. It is driven by innovation, unmet medical needs, and increasing global healthcare expenditure. The market is competitive, with major players and emerging biotechs vying for market share.
Positioning
COSCIENS Biopharma Inc. is positioned as an emerging biopharmaceutical company with a focus on developing disruptive therapies for serious diseases. Its competitive advantages lie in its proprietary technology platform, experienced scientific team, and a pipeline of potentially first-in-class or best-in-class drug candidates.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune disease therapies is substantial, estimated to be in the hundreds of billions of dollars globally. COSCIENS Biopharma Inc. aims to capture a significant portion of this market by addressing specific patient populations with high unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Experienced management and scientific team
- Pipeline with potentially innovative drug candidates
- Focus on significant unmet medical needs
Weaknesses
- Clinical trial risks and failures
- High R&D costs and long development timelines
- Limited commercial infrastructure (currently)
- Reliance on external funding
Opportunities
- Advancements in biotechnology and genomics
- Increasing demand for novel therapies
- Potential for strategic partnerships and collaborations
- Expansion into new therapeutic areas
Threats
- Regulatory challenges and delays
- Intense competition from established pharmaceutical companies
- Patent expirations and generic competition (for future products)
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Company A (Symbol)
- Company B (Symbol)
- Company C (Symbol)
Competitive Landscape
COSCIENS Biopharma Inc. faces a highly competitive landscape dominated by larger pharmaceutical companies with established market presence and significant resources. Its advantage lies in its targeted approach to specific diseases and potentially novel mechanisms of action, which can disrupt established treatment paradigms.
Growth Trajectory and Initiatives
Historical Growth: Historically, COSCIENS Biopharma Inc. has experienced growth in its R&D activities, expansion of its pipeline, and advancement of its lead candidates into later-stage clinical trials. Employee growth has also been a factor as the company scales its operations.
Future Projections: Future projections are contingent on the successful clinical development and regulatory approval of its drug candidates. Analyst estimates for future growth are highly speculative and depend on numerous factors, including clinical trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include the initiation of Phase II trials for CSCI-101, further pre-clinical research on CSCI-205, and efforts to secure additional funding through equity offerings or strategic partnerships.
Summary
COSCIENS Biopharma Inc. is an emerging biopharmaceutical company focused on developing innovative therapies. Its strengths lie in its proprietary technology and experienced team, while its weaknesses stem from the inherent risks and high costs of drug development. Significant opportunities exist in addressing unmet medical needs, but the company faces threats from intense competition and regulatory challenges. Success hinges on the effective progression of its drug pipeline through clinical trials and securing adequate funding.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC Edgar)
- Industry research reports
- Financial news outlets
- Biopharmaceutical industry databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About COSCIENS Biopharma Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2000-05-10 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.cosciensbio.com |
Full time employees 40 | Website https://www.cosciensbio.com | ||
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.